Ubiquitin-specific protease 14 (USP14) is known to play important roles in the development and progression of cancer, including colorectal cancer, since it modulates proteasomal function and cellular proteostasis. In the present study, investigators from Zhejiang University and collaborators demonstrated that the USP14 inhibitor AKOS, a Chikungunya virus inhibitor, performed well as a colorectal cancer therapeutic both in vitro and in vivo.
It is hardly news that tumor cells, compared to healthy ones, show metabolic reprogramming that accelerates the production of energy and biosynthetic precursors to support rapid growth. What is newly discovered, in contrast, is the possibility that hepatocellular carcinoma (HCC) tumors that are resistant to systemic therapies show further metabolic reprogramming beyond cells that are therapy sensitive, leading them to produce and store even greater amounts of energy.
Bayer AG and Kumquat Biosciences Inc. have entered into an exclusive global license and collaboration agreement to develop and commercialize Kumquat’s KRAS G12D inhibitor.
Cyclin-dependent kinase 6 (CDK6) plays a crucial role in the G1 phase to S phase transition of the cell cycle. Aberrant activation of CDK6 has been linked with the development and progression of cancers such as leukemia, lymphoma and solid tumors. A recent study published in Bioorganic & Medicinal Chemistry aimed to discover novel proteolysis-targeting chimera (PROTAC) molecules as CDK6 inhibitors.
Jiangsu Vcare Pharmatech Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Zhejiang University has synthesized isoquinoline derivatives reported to be useful for the treatment of cancer, infections, autoimmune disease, and cardiovascular, cerebrovascular and Inflammatory disorders.
LG Chem Ltd. has disclosed bromodomain-containing protein 4 (BD1 domain) (BRD4 BD1) and CREB-binding protein (CREBBP; CBP) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and autoimmune disease.
Lung cancer, which often occurs as lung adenocarcinoma, is the leading cause of cancer-related death worldwide. At least 70% of lung adenocarcinoma patients fail to show long-term benefit from immune checkpoint inhibitors, highlighting the need to identify in advance those more likely to benefit.
Researchers continue to search for how they can inhibit cancer metastasis as it can severely worsen prognosis, even if the primary tumor responded well to therapy. Researchers at Università degli Studi di Torino and collaborators previously showed that injecting an RNA aptamer targeting the miRNA miR-214, called anti-miR-214 sponge, reduced metastasis of tumors to lungs and liver. One drawback of this potential therapeutic approach was that the inhibitor oligo could enter all cells, not only tumors.
Triple-negative breast cancer (TNBC) accounts for a substantial proportion of all breast cancers and is the most aggressive form of the disease. Identifying potential therapeutic targets is critical because the cancer does not express the three surface receptors recognized by current targeted therapies.
RSS
